Thursday, March 07, 2024 9:03:07 AM
MindMed’s stock jumps 24% after FDA grants breakthrough designation to LSD therapy for a form of anxiety
By Ciara LinnaneFollow
Biotech also issues new shares and reports positive data from Phase 2b trial
Mind Medicine Inc.’s stock jumped 24% early Thursday, after the biotech company said the Food and Drug Administration has granted breakthrough designation for its MM120 LSD-based treatment for generalized anxiety disorder.
Published: March 7, 2024 at 8:26 a.m. ET
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM